Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine as an adjunct to MECT for refractory depression
ChiCTR2200057648Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Hamilton Depression Scale-24 total score. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200057648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057648.